



Gottfried Baier, PhD

Institute of Cell Genetics, Department for Genetics and Pharmacology

Medical University of Innsbruck,

Peter Mayr Str. 1a, A-6020 Innsbruck, Austria

Website: <http://www.baierlab.com/>

ORCID: 0000-0002-2085-8325

GOOGLE SCHOLAR: <https://scholar.google.com/citations?hl=de&user=a63VpW0AAAAJ>

E-mail: Gottfried.Baier@i-med.ac.at

Personal information

Place of Birth: Bludenz, Austria

Date of Birth: Feb 12, 1963

Citizenship: Austria

Acad. Degree: Univ.-Prof. Dr. rer nat

Education

1987-1989 Ph.D. thesis in medical microbiology, University of Innsbruck

1981-1986 Undergraduate studies, University of Innsbruck, Austria and Max-Planck-Institute for Molecular Genetics, Berlin, Germany (specialized in biochemistry).

Relevant Career History

Since 2016 Appointment as director of the Christian Doppler Laboratory for pharmacological cancer immunotherapy, Medical University of Innsbruck, Austria.

Since 2011 Appointment as full Professor (§98 Univ.-Prof.) at the Division for Translational Cell Genetics, Department for Pharmacology and Genetics, Medical University of Innsbruck.

Since 2009 Appointment as Director of the Division for Cell Genetics, Medical University of Innsbruck.

1997-2008 Tenure, Habilitation & Venia Docendi in "Human Genetics" and Associate Professor at the Department of Genetics, University of Innsbruck.

1994-1996 Univ.-Assistant, Institute for Human Genetics, University of Innsbruck, Austria.

1990-1993 Postdoctoral Fellow, La Jolla Institute for Allergy and Immunology, USA.

Key personal awards

2002: Novartis-Award for Biochemistry

1998: Hoechst/Sanofi-Award

1995: German Allergy and Immunology-Award

1995: Austrian Prof. Brandl-Award

Career-related activities

Since 2009: Director of the Institute for Translational Cell Genetics

Since 2007: Board member of EC FP7 SYBILLA and ONCOTYROL for Personalized Cancer Therapy

Since 2005: Faculty member of the FWF-funded Doctoral College "Molecular Cell Biology and Oncology" and supervisor committee member of numerous bachelor & master students

Since 2003: Board member of SFB021. "Cell Death in Tumours"

Since 2000: Member of several Austrian and European immunological societies

Since 1994: Academic teacher and examiner of lectures and seminars in genetics and signal transduction.

Reviewer activities

Journals: J. Clin. Inv., J. Exp. Med, Nature Commun, Blood, Proc Natl Acad Sci USA, .et al.

Funding agencies: Wellcome Trust (U.K.), Israel Science Foundation, Italian Telethon, French, Dutch and Swiss Science Foundations, German Science Foundations BMFWF and DFG.

Mentoring: As a member of the mentor and/or supervisor thesis committee, he has supervised >50 Master's degree and PhD students as well as >25 postdoctoral fellows, some of whom have gone on to become staff scientists and independent group leaders.

Major international academic cooperation partners

Amnon Altman, La Jolla Institute for Immunology, San Diego, USA: T cell signal transduction

Michael Leitges, Memorial University of Newfoundland, St. John's, Canada: Mouse genetics

Josef Penninger, Life Sciences Institute, Univ. of British Columbia, Canada: Systems biology

Research interests and major achievements

Research of his laboratory is focusing on molecular mechanisms signaling mediating tolerance induction versus clonal expansion of effector T lymphocyte. His team has focused on the physiological involvement of distinct PKC isotypes in specific immune cell functions, employing a set of single- and double PKC isotype gene knockout mice as well as specific and potent low molecular weight inhibitors generated by his BigPharma and SME partners. His achievements include the leading-edge discoveries of the central-staged PKC/Cbl-b and PKC/NR2F6 signaling pathways and their key role in the control of cancer immune surveillance. Gene ablation experiments have shown promising improvements in anti-tumour T cell responses, thereby validating particularly NR2F6 as an alternative and druggable cancer therapeutic drug target for next-generation immune-oncology regimens.

Recent funds obtained (5 most important ones)

ERC_ADV: Host protective engineering of cancer immunity; Acronym: HOPE	EC Horizon 2020	2018-2023
NR2F6 as bona-fide cancer immune checkpoint	Austrian Science Funds (FWF)	2018-2022
Relevance of NR2F6 as lymphatic biomarker	Austrian Central Bank OeNB	2018-2022
Immuno-regulatory role of A2A-receptor	Austrian Science Funds (FWF)	2017-2021
CD Laboratory for cancer immune therapy; Acronym: I-CARE	Christian Doppler Society (CDG)	2017-2020

Publications of Gottfried Baier: s. complete list on: <http://www.baierlab.com/>

>125 original publications and >20 invited reviews in peer reviewed journals or book chapters, 5 patents,

>100 invited lectures; h-index: 50, Cumulative Impact Factor: >1250, Cumulative Citations: > 9500

Version: March 2021

Gottfried Baier: 10 most important original publications

1. Klepsch V, Hermann-Kleiter N, Do-Dinh P, Jakic B, Offermann A, Efremova M, Sopper S, Rieder D, Krogsdam A, Gamerith G, Perner S, Tzankov A, Trajanoski Z, Wolf D, **Baier G**. Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade. **Nat Commun**. 2018 Apr 18;9(1):1538. doi: 10.1038/s41467-018-04004-2. PubMed PMID: 29670099.
2. Hermann-Kleiter N, Klepsch V, Wallner S, Siegmund K, Klepsch S, Tuzlak S, Villunger A, Kaminski S, Pfeifhofer C, Gruber T, Wolf D, **Baier G**. NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance. **Cell Reports** 2015 Sep 29;12(12):2072-85. doi:10.1016/j.celrep.2015.08.035. PMID: 26387951.
3. Gruber T, Hinterleitner R, Hermann-Kleiter N, Meisel M, Kleiter I, Wang CM, Viola A, Pfeifhofer-Obermair C, **Baier G**. Cbl-b mediates TGFbeta sensitivity by downregulating inhibitory SMAD7 in primary T cells. **J Mol Cell Biol**. 2013. doi: 10.1093/jmcb/mjt017. PMID: 23709694. [Epub ahead of print].
4. Meisel M, Hermann-Kleiter N, Hinterleitner R, Gruber T, Wachowicz K, Pfeifhofer-Obermair C, Fresser F, Leitges M, Soldani C, Viola A, Kaminski S, **Baier G**. The kinase PKC alpha selectively upregulates interleukin-17A during Th17 cell immune responses. **Immunity**. 2013;38(1):41-52. doi: 10.1016/j.immuni.2012.09.021. PMID: 23290522.
5. Hinterleitner R, Gruber T, Pfeifhofer-Obermair C, Lutz-Nicoladoni C, Tzankov A, Schuster M, Penninger JM, Loibner H, Lametschwandner G, Wolf D, **Baier G**. Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumour vaccine efficacy in a B16 melanoma model. **PLoS One**. 2012;7(9):e44295. doi: 10.1371/journal.pone.0044295. PubMed Central PMCID: PMC3433477.
6. Evenou JP, Wagner J, Zenke G, Brinkmann V, Wagner K, Kovarik J, Welzenbach KA, Weitz-Schmidt G, Guntermann C, Towbin H, Cottens S, Kaminski S, Letschka T, Gruber T, Hermann-Kleiter N, Thuille N, **Baier G**. The potent PKC-selective inhibitor AEB071/Sotrastaurin represents a new class of immunosuppressive agents affecting early T-cell activation. **J Pharmacol Exp Ther**. 2009. 330:792-801.
7. Gruber T, Hermann-Kleiter N, Hinterleitner R, Fresser F, Schneider R, Gastl G, Penninger JM, **Baier G**. PKCtheta modulates the strength of T cell responses by targeting Cbl-b for ubiquitination and degradation. **Science Signalling**. 2009. 2(76):ra30. doi: 10.1126/scisignal.2000046. PMID: 19549985.
8. Hermann-Kleiter N, Gruber T, Lutz-Nicoladoni C, Thuille N, Fresser F, Labi V, Schiefermeier N, Warnecke M, Huber LA, Villunger A, Eichele G, Kaminski S, **Baier G**. NR2F6 suppresses lymphocyte activation and Th17-dependent autoimmunity. **Immunity**. 2008 Aug;29(2):205-16. PMID: 18701084.
9. Pfeifhofer C, Kofler K, Gruber T, Tabrizi NG, Lutz C, Maly K, Leitges M, **Baier G**. PKCtheta affects Ca²⁺ mobilization and NFAT activation in T cells. **J Exp Med**. 2003 Jun 2;197(11):1525-35. PMID: 12782715.
10. **Baier G**, Telford D, Giampa L, Coggeshall KM, Baier-Bitterlich G, Isakov N, Altman A. Molecular cloning and characterization of PKCtheta, a novel member of the PKC gene family expressed predominantly in hematopoietic cells. **J Biol Chem**. 1993 Mar 5;268(7):4997-5004. PMID: 8444877.